Core 1: Biospecimen/Pathology

核心 1：生物样本/病理学

• 批准号: 10263345
• 负责人: Shannon Jones McCall
• 金额: $ 10.02万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-14 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10263345
• 关键词: Accreditation; African American; American; Award; Bioinformatics; Biological; Biomedical Research; Biopsy; Blood; Blood specimen; Cancer Center Support Grant; Cancer Model; Catchment Area; Cell Culture Techniques; Clinical; Clinical Research; Collection; Colon Carcinoma; Communities; Community Outreach; Consent; Cooperative Human Tissue Network; Country; Data; Data Analyses; Development; Ensure; Equipment and supply inventories; Ethnic Origin; Exposure to; Fresh Tissue; Funding; Future; Generations; Goals; Helicobacter pylori; Histology; Immunohistochemistry; Informed Consent; Institutes; International; KRASG12D; Libraries; Link; Liquid substance; Malignant Neoplasms; Malignant neoplasm of lung; Minority Groups; Minority Participation; Modeling; Molecular; Mutate; Neoadjuvant Therapy; Neoplasm Metastasis; Nucleic Acids; Participant; Pathologist; Pathology; Patients; Pilot Projects; Primary Neoplasm; Process; Protocols documentation; Race; Research; Research Design; Research Institute; Research Personnel; Research Project Grants; Resource Sharing; Retrospective cohort; Sampling; Services; Societies; Specimen; Stomach; Therapeutic Intervention; Tissue Procurements; Tissue Sample; Tissues; Translational Research; Trust; Underrepresented Minority; Underrepresented Populations; Update; base; biobank; black patient; cancer health disparity; career development; cohort; college; community engagement; data registry; health equity; human model; improved; innovation; meetings; metabolomics; molecular phenotype; patient derived xenograft model; programs; repository; sample collection; success; transcriptome sequencing; translational cancer research; tumor registry

ABSTRACT – Biospecimen/Pathology Core (Core 1) The Biospecimen/Pathology Core of the Duke Cancer Health Disparities P20 SPORE (DCHD) leverages and is housed in the Duke Cancer Institute’s BioRepository & Precision Pathology Center (BRPC). The BRPC is a Shared Resource of the Duke Cancer Institute and supported in part by the Duke Cancer Center Support Grant (5P30-CA014236-45). This NCI-funded shared service center obtains broad consent from patients for blood and tissue sample donation and procures, processes and banks both liquid and tissue biospecimens, supports Duke’s “living biobank” with the Duke Patient-Derived Xenograft and Primary Tumor Cell Culture Services, and implements bioinformatic and clinical strategies for precise sample and model annotation. For the DCHD, the Core will efficiently provide high-quality tissue, blood and fluid-based biospecimens and processing services to requesting investigators, and continue to adjust practices as researcher needs evolve (Aim 1); support current and future DCHD P20 projects through expansion of existing best practices in tissue procurement, processing, and sample management (Aim 2); and educate the local, regional and national community on the importance of available biospecimens in biomedical research to enhance availability of specimens and data from underrepresented minorities (Aim 3). The Duke BRPC has recently been awarded an NCI UM1 to join the Cooperative Human Tissue Network (CHTN)(www.chtn.org); this network of biorepositories will support deeper cohort generation from across the country. For the proposed Projects, we will provide appropriate lung cancer specimens and associated data from multiple races/ethnicities (Project 1), and stomach biopsies positive for H. pylori from Black patients (Project 2). The needs of future Pilot Projects will be assessed for feasibility; given the BRPC’s existing library, a recent focus on underrepresented minority inclusion, and CHTN participation, a wide range of cancer disparities research should be possible. This Core is fully integrated into the DCHD and is critical for its success.

摘要 – 生物样本/病理学核心（核心 1） 杜克癌症健康差异 P20 SPORE (DCHD) 的生物样本/病理学核心利用并 位于杜克癌症研究所的生物储存库和精密病理学中心 (BRPC)。 BRPC 是一个 杜克癌症研究所的共享资源，并由杜克癌症中心支持基金提供部分支持 (5P30-CA014236-45)。这家由 NCI 资助的共享服务中心获得了患者的广泛同意，提供血液和 组织样本捐赠和采购、处理和储存液体和组织生物样本，支持 杜克大学的“活体生物库”以及杜克大学患者来源的异种移植和原代肿瘤细胞培养服务，以及 实施生物信息学和临床策略以进行精确的样本和模型注释。对于 DCHD 来说， Core 将高效地为以下领域提供高质量的组织、血液和液体生物样本及处理服务： 要求研究人员，并根据研究人员需求的变化继续调整实践（目标 1）；支持电流 和未来的 DCHD P20 项目，通过扩展组织采购、加工、 和样品管理（目标 2）；并教育地方、区域和国家社区认识到 生物医学研究中可用的生物样本，以提高样本和数据的可用性 代表性不足的少数群体（目标 3）。杜克 BRPC 最近被授予 NCI UM1 加入 人体组织合作网络（CHTN）（www.chtn.org）；该生物样本库网络将支持 来自全国各地的更深入的群体一代。对于拟议的项目，我们将提供适当的 来自多个种族/民族的肺癌标本和相关数据（项目 1）以及胃活检 黑人患者的幽门螺杆菌呈阳性（项目 2）。将评估未来试点项目的需求 可行性;考虑到 BRPC 现有的图书馆、最近关注代表性不足的少数族裔包容性以及 CHTN 参与，广泛的癌症差异研究应该是可能的。该核心完全集成到 DCHD 对其成功至关重要。